August 18, 2025 – Akumin, a national leader in outpatient radiology and oncology services, has selected Lunit INSIGHT DBT, a leading AI solution for early breast cancer detection. The decision marks a key step in Akumin’s plans to integrate advanced technologies that elevate care delivery and expand patient access to precision diagnostics.
“We are very excited to have an AI solution that meets our high standards of clinical excellence and that we believe will make a meaningful difference for the patients we serve, and the radiologists who care for them,” said Dr. Nasir Siddiqui, Chief Medical Officer at Akumin. “Lunit stands out with strong clinical validation and proven real-world performance. Their technology reflects our commitment to innovation in care and ensures our patients benefit from the most advanced tools in early cancer detection.”
Lunit INSIGHT MMG and DBT are backed by more than 100 peer-reviewed publications and are FDA cleared for 2D and 3D use, respectively, with proven effectiveness in improved detection of early-stage cancers while reducing false positives.
Hospitals and physician groups are under pressure to expand access to outpatient radiology and oncology services to keep up with the growing demand. Still, they face steep hurdles like staffing shortages, rising capital costs and lengthy construction timelines. In addition to operating over 150 fixed sites across the United States, Akumin is uniquely addressing this gap by delivering scalable imaging solutions through its outpatient model, providing healthcare systems with an efficient alternative to building and staffing in-house capabilities, while ensuring patients receive timely diagnostics when and where they need them.
“Akumin’s model is transforming how care is delivered across the U.S., and we’re proud to support that mission,” said Brandon Suh, CEO of Lunit. “Akumin’s investment in Lunit INSIGHT DBT reflects a strategic, evidence-based approach to solving some of the most pressing challenges in diagnostic imaging. It also builds on the growing momentum we’ve seen in the U.S. market, where Lunit’s breast screening AI is being implemented in over 200 imaging centers nationwide. When radiologists are equipped with best-in-class AI, patients benefit from earlier detection, greater accuracy, and ultimately, better outcomes, when it matters most.”
For more information, please visit akumin.com/ or lunit.io.
February 18, 2026 
